Airway Sensory Neural Remodeling in ENT Disorders

Abstract

Airway sensory neural remodeling is increasingly recognized as a pivotal mechanism underpinning the pathophysiology and clinical heterogeneity of numerous ENT (Ear, Nose, and Throat) disorders. This review synthesizes current evidence on airway sensory neural remodeling, focusing on its epidemiological significance, underlying mechanisms, risk factors, clinical manifestations, diagnostic modalities, and therapeutic strategies. Special emphasis is placed on recent advances and guideline-based recommendations, with the aim of providing clinicians and researchers with a comprehensive resource for optimizing patient outcomes in ENT practice.

Introduction

The upper airway is richly innervated by sensory nerves that regulate protective reflexes, mucosal integrity, and immune responses. In ENT disorders such as chronic rhinosinusitis, allergic rhinitis, laryngopharyngeal reflux, and chronic cough, aberrant sensory neural remodeling contributes to symptom persistence and disease chronicity. Understanding the mechanisms and clinical implications of airway sensory neural remodeling has become essential in modern otolaryngology, as it informs both diagnostic and therapeutic approaches.

Epidemiology / Disease Burden

ENT disorders with a neurogenic component, including chronic rhinosinusitis, non-allergic rhinitis, and chronic cough, affect a significant proportion of the global population. Chronic rhinosinusitis alone impacts up to 10-15% of adults, while chronic cough afflicts 5-10%. The burden is compounded by reduced quality of life, increased healthcare utilization, and frequent comorbidity with asthma, gastroesophageal reflux disease, and allergic conditions. Sensory neural remodeling is a common thread that links these diverse clinical entities, contributing to symptom persistence, treatment failure, and disease recurrence.

Pathophysiology

Airway sensory neural remodeling refers to structural and functional changes in sensory nerve fibers and their microenvironment. These changes include increased nerve density, aberrant sprouting, altered expression of neuropeptides (e.g., substance P, calcitonin gene-related peptide), and upregulation of ion channels such as TRPV1 and sodium channels. Inflammatory mediators, epithelial-derived cytokines, and neurotrophic factors like nerve growth factor (NGF) drive these processes. The result is heightened neural excitability, aberrant reflexes, and neurogenic inflammation, which perpetuate symptoms such as cough, sneezing, nasal congestion, and throat discomfort.

Risk Factors

Multiple factors predispose individuals to airway sensory neural remodeling. Chronic inflammation due to viral infections, allergens, or environmental irritants initiates and sustains neural plasticity. Genetic predisposition, atopy, occupational exposures (e.g., dust, fumes), and comorbid systemic diseases (e.g., diabetes, autoimmune conditions) further modulate risk. Iatrogenic factors, such as repeated surgical interventions or aggressive topical therapies, can also induce neurogenic changes in the upper airway mucosa.

Clinical Features

Patients with sensory neural remodeling often present with refractory or atypical symptoms. In chronic rhinosinusitis and non-allergic rhinitis, these may include persistent nasal obstruction, paradoxical nasal hyperreactivity, and facial pain disproportionate to clinical findings. In laryngeal disorders, chronic cough, globus sensation, and throat clearing are common. These symptoms are often exacerbated by innocuous stimuli, reflecting altered neural thresholds and sensitization. Standard anti-inflammatory or antihistamine therapies may be ineffective, underscoring the neurogenic contribution to disease.

Diagnosis

Diagnosis of airway sensory neural remodeling is primarily clinical but can be supported by objective tests. Nasal or laryngeal challenge tests with capsaicin or histamine can demonstrate hyperresponsiveness. Imaging studies (e.g., MRI, CT) may reveal mucosal thickening or structural changes, but they lack specificity for neural remodeling. Nasal biopsies and immunohistochemical staining for neural markers (e.g., PGP9.5, TRPV1) are research tools rather than routine diagnostics. Emerging electrophysiological approaches and molecular assays hold promise for noninvasive assessment of neural function and remodeling in the clinical setting.

Treatment & Management

Therapeutic strategies target both the underlying inflammation and neural dysfunction. Topical and systemic corticosteroids remain mainstays for inflammatory control. In cases of prominent neural symptoms, neuromodulatory agents such as gabapentin, amitriptyline, and pregabalin are increasingly utilized. Capsaicin nasal sprays and botulinum toxin injections have demonstrated efficacy in select refractory cases by desensitizing hyperactive sensory nerves. Patient education, avoidance of triggers, and multidisciplinary management are crucial, particularly in complex or treatment-resistant cases.

Recent Advances / Emerging Therapies

Recent advances in understanding the molecular drivers of sensory neural remodeling have spurred novel therapeutic approaches. TRP channel antagonists, neurokinin receptor inhibitors, and biologics targeting eosinophilic inflammation show promise in preclinical and early clinical trials. Modulation of neurotrophic pathways (e.g., anti-NGF therapies) represents a frontier in reducing neural hyperplasia and excitability. Advances in high-resolution imaging and noninvasive biomarkers are poised to enhance diagnostic precision and guide personalized therapy in the near future.

Guideline Recommendations

Current ENT guidelines recognize the neurogenic contributions to chronic airway disorders and advocate a multimodal approach. The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) and American Academy of Otolaryngology guidelines recommend adjunctive use of neuromodulators in refractory cases, alongside standard anti-inflammatory therapy. Regular reassessment, patient-tailored treatment plans, and early referral to subspecialty care are emphasized for optimizing outcomes in patients with neural remodeling features.

Conclusion

Airway sensory neural remodeling is a critical pathophysiological process in a spectrum of ENT disorders, influencing symptomatology, disease course, and response to therapy. Advances in molecular understanding and targeted therapeutics offer new hope for patients with neurogenic disease phenotypes. Integrating mechanistic insights, guideline-based care, and emerging interventions will be essential for improving clinical outcomes and quality of life in patients with sensory neural remodeling of the upper airway.